VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Understanding the mechanisms of resistance to TKIs in CML to help choose better treatment strategies

Camille Kockerols, MD, Albert Schweitzer Hospital, Dordrecht, Netherlands, talks about mechanisms of resistance to tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) and the challenge this poses in administrating the most effective treatment regimens to patients, commenting on primary and secondary resistance as well as the impact of BCR-ABL mutations on treatment resistance. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter